Founder & President

Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025

Krystal Biotech’s FDA Platform Designation Pushes Limits of the Award

Krystal Biotech price target raised by $73 at BofA, here's why

Krystal Biotech gets FDA platform technology designation to HSV-1 viral vector

Key Account Manager / Field Gene Therapy Lead

Krystal Biotech, Inc. is a company focused on the discovery and commercialization of genetic medicines. They are seeking a Gene Therapy Lead to improve the patient journey and engage with key stakeholders to facilitate the launch of their treatment for Dystrophic Epidermolysis Bullosa in Southern Italy.

Sign up with Google

Sign in with Google